Transaction Details

Footnotes

The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.01 to $10.17, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. | MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.98 to $10.17, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.99 to $10.06, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. | This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.